| Field | Specification |
|---|---|
| Target | |
| Alternative names | B- and T-lymphocyte attenuator; B- and T-lymphocyte-associated protein; CD272; BTLA |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | A synthetic peptide corresponding to a sequence in the middle region of human CD272/BTLA. |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody detects B- and T-lymphocyte attenuator (gene BTLA) in human and mouse samples and is validated for flow cytometry, IHC, ICC/IF and Western blot. The predicted molecular weight is 32.8 kDa, and the supplier reports an observed band at about 65 kDa.
BTLA (CD272) is an inhibitory immunoglobulin superfamily receptor on B and T lymphocytes and dendritic cells. Binding to its ligand HVEM (TNFRSF14) leads to recruitment of the phosphatases SHP-1 and SHP-2, which dampen antigen receptor signaling. BTLA is studied as an immune checkpoint in autoimmunity, infection and tumor immunology.
| Target | B- and T-lymphocyte attenuator (gene BTLA; UniProt Q7Z6A9, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human, Mouse |
| Form | Lyophilized |
| Formulation | Per vial: 4 mg trehalose; 0.9 mg NaCl; 0.2 mg Na2HPO4; 0.05 mg NaN3 |
| Calculated MW | 32.8 kDa |
| Observed MW | 65 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.1–0.5 µg/mL |
|---|---|
| IHC (paraffin sections) | 0.5–1 µg/mL |
| IHC (frozen sections) | 0.5–1 µg/mL |
| Immunocytochemistry / Immunofluorescence | 0.5–1 µg/mL |
| Flow cytometry (fixed cells) | 1–3 µg/1×106 cells |
Samples with a confirmed band (WB): human HEK293 cells, human Jurkat cells, human CCRF-CEM cells, mouse thymus tissue.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 50 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:10000, ECL detection.
Samples with confirmed staining (IHC): mouse spleen tissue, human tonsil tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in citrate buffer (pH 6).
Samples with a confirmed signal (flow cytometry): THP-1 cells.
Immunogen
Synthetic peptide from the middle region of human CD272/BTLA.
Reactivity Notes
The supplier lists reactivity with human and mouse. UniProt places B- and T-lymphocyte attenuator in the cell membrane. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
Liu Xuechao et al. (2024) Deciphering the tumor immune microenvironment of imatinib-resistance in advanced gastrointestinal stromal tumors at single-cell resolution. Cell Death & Disease. 10.1038/s41419-024-06571-3
